Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | VNN1 | O95497 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137497 | 0.86 | MAP2K4 (0.54) | MAPK1VNN1JAK2PDPK1MAP2K4 | |
| SCHEMBL24137524 | 0.86 | SGK1 (0.48) | GSK3BVNN1SCN5ASCN9AJAK2 | |
| SCHEMBL24137503 | 0.84 | MAP2K4 (0.55) | MAPK1SCN5ASCN9AJAK2PDPK1 | |
| SCHEMBL25933252 | 0.84 | JAK2 (0.52) | SCN5ASCN9AJAK2PDPK1FGFR1 | |
| SCHEMBL24137526 | 0.83 | BTK (0.45) | SCN5ASCN9AJAK2PDPK1MAP2K4 | |
| SCHEMBL6479125 | 0.83 | JAK2 (0.60) | GSK3BTRPA1SCN5ASCN9AJAK2 | |
| SCHEMBL25933239 | 0.82 | ABL1 (0.54) | JAK2PDPK1ABL1BCR | |
| SCHEMBL24137502 | 0.82 | JAK2 (0.48) | VNN1JAK2PDPK1 | |
| SCHEMBL24137787 | 0.82 | JAK2 (0.61) | GSK3BSCN5ASCN9AJAK2PDPK1 | |
| SCHEMBL24137528 | 0.81 | BTK (0.51) | SCN5ASCN9AJAK2PDPK1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| WO-2021263129-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | MAPK1 98/4885GSK3B 267/4885TRPA1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.